ChemoMetec A/S (CPH:CHEMM)

Denmark flag Denmark · Delayed Price · Currency is DKK
321.60
+16.60 (5.44%)
May 6, 2026, 4:59 PM CET
Market Cap5.31B -36.2%
Revenue (ttm)493.12M +7.3%
Net Income177.03M +4.7%
EPS10.17 +4.6%
Shares Out17.40M
PE Ratio29.99
Forward PE25.18
Dividend7.00 (2.30%)
Ex-Dividend DateOct 10, 2025
Volume16,393
Average Volume77,545
Open310.60
Previous Close305.00
Day's Range307.00 - 323.20
52-Week Range235.20 - 804.00
Beta1.34
RSI45.46
Earnings DateSep 10, 2026

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202... [Read more]

Sector Healthcare
Founded 1997
Employees 172
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol CHEMM
Full Company Profile

Financial Performance

In fiscal year 2025, ChemoMetec's revenue was 495.57 million, an increase of 21.50% compared to the previous year's 407.87 million. Earnings were 186.41 million, an increase of 36.78%.

Financial Statements

News

ChemoMetec Earnings Call Transcript: Q1 2026

Revenue grew 8% year-over-year with strong XM platform adoption and improved margins. Upgraded guidance reflects broad customer interest, with larger XM orders expected by fiscal year-end. Strategic focus is on software and automation, supporting long-term profitability.

6 months ago - Transcripts

Full Year 2025 Chemometec A/S Earnings Call Transcript

Full Year 2025 Chemometec A/S Earnings Call Transcript

6 months ago - GuruFocus

ChemoMetec Earnings Call Transcript: Q4 2025

Revenue, EBITDA, and cash flow increased year-over-year, with strong growth across all segments and a high gross margin. Guidance anticipates 10–14% sales growth, margin improvement, and major investments in automation and software, while macro and currency risks remain.

8 months ago - Transcripts

Half Year 2025 Chemometec A/S Earnings Call Transcript

Half Year 2025 Chemometec A/S Earnings Call Transcript

1 year ago - GuruFocus